A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex ® , nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole...
Saved in:
| Published in | SpringerPlus Vol. 2; no. 1; p. 236 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
24.05.2013
Springer Nature B.V BioMed Central Ltd Springer International Publishing AG |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex
®
, nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole).
Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC).
A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the C
max
and AUC of all analytes. C
max
reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the C
max
of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in C
max
or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole.
Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.
Trials registration
NCT01323465 |
|---|---|
| AbstractList | This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.
NCT01323465. This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex ®, nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole).Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC).A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole.Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole. TRIALS REGISTRATION: NCT01323465 This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.ABSTRACTThis Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.NCT01323465.TRIALS REGISTRATIONNCT01323465. This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex ® , nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the C max and AUC of all analytes. C max reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the C max of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in C max or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole. Trials registration NCT01323465 This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of [Delta]9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex , nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the C max of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole. Trials registration NCT01323465 |
| ArticleNumber | 236 |
| Author | Wilbraham, Darren Guy, Geoffrey Wright, Stephen White, Linda Stott, Colin |
| Author_xml | – sequence: 1 givenname: Colin surname: Stott fullname: Stott, Colin email: cgs@gwpharm.com organization: GW Pharma Ltd – sequence: 2 givenname: Linda surname: White fullname: White, Linda organization: GW Pharma Ltd – sequence: 3 givenname: Stephen surname: Wright fullname: Wright, Stephen organization: GW Pharma Ltd – sequence: 4 givenname: Darren surname: Wilbraham fullname: Wilbraham, Darren organization: Quintiles Drug Research Unit at Guy's Hospital – sequence: 5 givenname: Geoffrey surname: Guy fullname: Guy, Geoffrey organization: GW Pharma Ltd |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23750331$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Uk1v1DAQjVARLaVnbsgSFw4bNk42yeaC1C4frahUhMrZmjiTXRfHE2xnpe0v5efg7LbVtqIjWf567_l5Zl5HB4YMRtFbnnzkfF5MU15lMZ8nPE7jNCteREcPJwd768PoxLmbJERR8lmZvIoO06zMkyzjR9HfU_ZjBQ7ZxYRRjybWUKOeMAumoU7dYjNh0pJztEbLnB-aDVOG-ZVFZD1Y0Bo1W1oaesc8MVyDHsBjQCDDtkXpGbXsp2qh65VUZsK-oydJBm5J44SFd9hVh73d7hmZLbNfge1A0m9l0CvpRo3r88V0cfaZkaVukORAMxdoWz8rBO1XG7YmPRiPaN2b6GUL2uHJ3Xwc_fr65XpxHl9efbtYnF7GdZ5yH8OMh9RBhTyfySovqzarZzBvi7LgdVNkJUeAJi1RVu08QSyhlnmDZZrMq6Zq2-w4-rTT7Ye6w0ai8SEporeqA7sRBEo8vjFqJZa0FlmoRoggcLYTqBU9I_D4RlInxuKKsbgiFcF_EPlw58LSnwGdF51yErUGgzQ4wYu0GEc5Qt8_gd7QYE3IURAsAirPkySg3u1_68HOfecEQL4DbLvDYiuk8uAVjSaVFjwRY5P-x-n0Ce9e-nlGsmOEaiuzRLtn-BnKP8iw_As |
| CitedBy_id | crossref_primary_10_1016_j_therap_2023_05_003 crossref_primary_10_3390_jcm11051154 crossref_primary_10_1002_jcph_1871 crossref_primary_10_3389_fphar_2020_586110 crossref_primary_10_3389_fphar_2016_00309 crossref_primary_10_1016_j_lfs_2023_121838 crossref_primary_10_3390_jcm8070989 crossref_primary_10_1097_JCP_0000000000000707 crossref_primary_10_3390_pharmaceutics14122733 crossref_primary_10_1002_ptr_7050 crossref_primary_10_2174_0113816128288510240113170116 crossref_primary_10_3238_PersOnko_2018_11_23_05 crossref_primary_10_1007_s15010_017_1042_z crossref_primary_10_1186_s42238_024_00256_6 crossref_primary_10_1007_s40265_017_0720_6 crossref_primary_10_1038_s41467_025_55863_5 crossref_primary_10_3390_pharmaceutics17030319 crossref_primary_10_1097_TP_0000000000003309 crossref_primary_10_1007_s40122_022_00465_y crossref_primary_10_1177_2054358119828391 crossref_primary_10_1007_s40267_017_0410_1 crossref_primary_10_3390_cimb45040228 crossref_primary_10_1097_JCP_0000000000001089 crossref_primary_10_3897_pharmacia_67_e51304 crossref_primary_10_1002_jcph_1387 crossref_primary_10_1159_000512189 crossref_primary_10_1016_j_clinthera_2017_01_011 crossref_primary_10_1038_s41598_022_17704_z crossref_primary_10_1586_14737175_2014_971758 crossref_primary_10_3390_toxins13020117 crossref_primary_10_1002_phar_2377 crossref_primary_10_1007_s11916_023_01144_z crossref_primary_10_3390_jcm11133717 crossref_primary_10_3390_molecules28062791 crossref_primary_10_1016_j_pharmthera_2017_08_014 crossref_primary_10_2174_1570159X17666190603171901 crossref_primary_10_1124_dmd_120_000350 crossref_primary_10_1124_dmd_118_085548 crossref_primary_10_1007_s13346_023_01444_2 crossref_primary_10_1016_j_forsciint_2016_03_031 crossref_primary_10_1016_j_jddst_2023_105316 crossref_primary_10_1002_psp4_12908 crossref_primary_10_3389_fphar_2018_01365 crossref_primary_10_3390_pharmaceutics16040484 crossref_primary_10_1016_j_bpa_2020_06_004 crossref_primary_10_1016_j_toxac_2023_10_004 crossref_primary_10_2174_2210676613666230901143219 crossref_primary_10_1007_s40265_019_01171_4 crossref_primary_10_1111_bcp_13710 crossref_primary_10_1177_0269881119872206 crossref_primary_10_1080_17512433_2023_2276309 crossref_primary_10_1089_can_2023_0025 crossref_primary_10_1016_j_reprotox_2019_05_064 crossref_primary_10_1213_ANE_0000000000006070 crossref_primary_10_1016_j_neuropharm_2020_108442 crossref_primary_10_3390_ph17020244 crossref_primary_10_1016_j_yebeh_2015_04_009 crossref_primary_10_1016_j_ejps_2025_107036 crossref_primary_10_1016_j_ejim_2021_05_002 crossref_primary_10_1016_j_pharmthera_2020_107621 crossref_primary_10_3238_arztebl_m2023_0223 crossref_primary_10_1089_can_2015_0012 crossref_primary_10_1007_s40265_014_0197_5 crossref_primary_10_1016_j_curtheres_2023_100709 crossref_primary_10_1159_000497361 crossref_primary_10_3390_jcm9040919 crossref_primary_10_3390_ph17121644 crossref_primary_10_3390_molecules27217573 crossref_primary_10_1016_j_bcp_2024_116191 crossref_primary_10_1080_17425255_2024_2309213 crossref_primary_10_14581_jer_17012 crossref_primary_10_1016_j_jpba_2024_116174 crossref_primary_10_1089_can_2017_0040 crossref_primary_10_1080_03602532_2019_1697283 crossref_primary_10_1007_s40263_020_00741_5 crossref_primary_10_1111_cts_13812 crossref_primary_10_1124_dmd_121_000823 crossref_primary_10_1002_ptr_6651 crossref_primary_10_1155_2016_4028492 crossref_primary_10_1007_s40262_016_0400_9 crossref_primary_10_1080_19390211_2021_2005733 crossref_primary_10_1177_1756285615612659 crossref_primary_10_1111_epi_16093 crossref_primary_10_1517_14656566_2014_918102 crossref_primary_10_1089_can_2019_0037 |
| Cites_doi | 10.1016/j.bcp.2010.01.028 10.1093/jat/19.2.91 10.1186/1476-0711-5-3 10.1007/s00415-012-6739-4 10.1016/j.pain.2007.08.028 10.1021/tx700079z 10.1016/j.jpainsymman.2009.06.008 10.1111/j.1476-5381.2011.01238.x 10.1016/j.clinthera.2007.09.013 10.2133/dmpk.20.153 10.1007/s12035-007-0005-2 10.1016/j.bcp.2005.07.007 10.1124/pr.54.2.161 10.1300/J175v01n03_12 10.1093/jat/19.6.419 10.1002/cbdv.200790152 10.1016/j.jpain.2012.01.003 10.1080/08998280.2000.11927719 10.1002/j.1875-9114.1998.tb03830.x |
| ContentType | Journal Article |
| Copyright | Stott et al.; licensee Springer. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. SpringerPlus is a copyright of Springer, 2013. Stott et al.; licensee Springer. 2013 |
| Copyright_xml | – notice: Stott et al.; licensee Springer. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: SpringerPlus is a copyright of Springer, 2013. – notice: Stott et al.; licensee Springer. 2013 |
| DBID | C6C AAYXX CITATION NPM 3V. 7X2 8FE 8FG 8FH 8FK ABJCF AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI BKSAR CCPQU D1I DWQXO GNUQQ HCIFZ JQ2 K7- KB. L6V LK8 M0K M7P M7S P5Z P62 PATMY PCBAR PDBOC PHGZM PHGZT PKEHL PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 5PM |
| DOI | 10.1186/2193-1801-2-236 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Agricultural Science Collection ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Earth, Atmospheric & Aquatic Science Collection ProQuest One ProQuest Materials Science Collection ProQuest Central Korea ProQuest Central Student SciTech Premium Collection ProQuest Computer Science Collection Computer Science Database Materials Science Database ProQuest Engineering Collection Biological Sciences Agriculture Science Database Biological Science Database Engineering Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Environmental Science Database Earth, Atmospheric & Aquatic Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Agricultural Science Database Computer Science Database ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Computer Science Collection Materials Science Collection SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China Earth, Atmospheric & Aquatic Science Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Engineering Collection Natural Science Collection ProQuest Central Korea Agricultural & Environmental Science Collection Biological Science Collection Materials Science Database ProQuest Central (New) Engineering Collection ProQuest Materials Science Collection Advanced Technologies & Aerospace Collection Engineering Database ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Earth, Atmospheric & Aquatic Science Database Agricultural Science Collection ProQuest Technology Collection Biological Science Database ProQuest SciTech Collection Environmental Science Collection Advanced Technologies & Aerospace Database ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2193-1801 |
| EndPage | 236 |
| ExternalDocumentID | PMC3671111 oai_biomedcentral_com_2193_1801_2_236 4312882001 23750331 10_1186_2193_1801_2_236 |
| Genre | Journal Article |
| GroupedDBID | -A0 0R~ 4.4 40G 53G 5VS 7X2 7XC 8CJ 8FE 8FG 8FH AAKKN ABEEZ ABJCF ACACY ACGFO ACGFS ACIWK ACPRK ACULB ADBBV ADINQ ADRAZ AEGXH AENEX AEUYN AFGXO AFKRA AFRAH AHBYD AHSBF AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ARAPS ATCPS BAWUL BBNVY BENPR BGLVJ BHPHI BKSAR C24 C6C CCPQU CZ9 D1I D1J D1K DIK EBS EJD GROUPED_DOAJ GX1 HCIFZ HH5 HYE HZ~ K6- K6V K7- KB. KC. KQ8 L6V LK5 LK8 M0K M48 M7P M7R M7S M~E O9- OK1 P62 PATMY PCBAR PDBOC PGMZT PTHSS PYCSY RNS RPM RSV SHS SOJ AAYXX CITATION PHGZM PHGZT 2VQ ABDBF ACUHS NPM 3V. 8FK AZQEC DWQXO GNUQQ JQ2 PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 AAYZJ AFNRJ AHBXF 5PM |
| ID | FETCH-LOGICAL-b521t-a41236a9e154c9579f3b4a8f6761bd6371eaad27ec9f80ee7abc5de72089d9ff3 |
| IEDL.DBID | M48 |
| ISSN | 2193-1801 |
| IngestDate | Thu Aug 21 18:30:07 EDT 2025 Tue Apr 16 22:43:32 EDT 2024 Fri Jul 11 05:14:20 EDT 2025 Fri Jul 25 09:40:15 EDT 2025 Wed Feb 19 01:54:33 EST 2025 Thu Apr 24 23:11:37 EDT 2025 Tue Jul 01 01:21:38 EDT 2025 Fri Feb 21 02:35:25 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Delta-9-tetrahydrocannabinol Cannabidiol Sativex Nabiximols Cytochrome P450 THC/CBD spray |
| Language | English |
| License | http://creativecommons.org/licenses/by/2.0 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b521t-a41236a9e154c9579f3b4a8f6761bd6371eaad27ec9f80ee7abc5de72089d9ff3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/2193-1801-2-236 |
| PMID | 23750331 |
| PQID | 1866165500 |
| PQPubID | 2034663 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3671111 biomedcentral_primary_oai_biomedcentral_com_2193_1801_2_236 proquest_miscellaneous_1626162676 proquest_journals_1866165500 pubmed_primary_23750331 crossref_citationtrail_10_1186_2193_1801_2_236 crossref_primary_10_1186_2193_1801_2_236 springer_journals_10_1186_2193_1801_2_236 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20130524 |
| PublicationDateYYYYMMDD | 2013-05-24 |
| PublicationDate_xml | – month: 5 year: 2013 text: 20130524 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Switzerland – name: Heidelberg |
| PublicationTitle | SpringerPlus |
| PublicationTitleAbbrev | SpringerPlus |
| PublicationTitleAlternate | Springerplus |
| PublicationYear | 2013 |
| Publisher | Springer International Publishing Springer Nature B.V BioMed Central Ltd Springer International Publishing AG |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V – name: BioMed Central Ltd – name: Springer International Publishing AG |
| References | (CR8) 2012 Langford, Mares, Novotna, Vachova, Novakova, Notcutt, Ratcliffe (CR18) 2013; 260 DiPiro (CR5) 1999 Ogu, Maxa (CR22) 2000; 13 (CR6) 2012 Howlett, Barth, Bonner (CR13) 2002; 54 Nurmikko, Serpell, Hoggart, Toomey, Morlion, Haines (CR21) 2007; 133 Foltz, McGinnis, Chinn (CR9) 1983; 10 Rog, Nurmikko, Friede, Young (CR25) 2005; 8 Rog, Nurmikko, Young (CR26) 2007; 29 Miller, Miller (CR20) 1992 Goodall, Basteyns (CR11) 1995; 19 Porteney, Ganae-Motan, Allende (CR24) 2012; 13 Pertwee (CR23) 2007; 36 Stott, White, Wright, Wilbraham, Guy (CR28) 2012 Michalets (CR19) 1998; 18 Bland, Haining, Tracy, Callery (CR1) 2005; 70 Chen, Raymond (CR2) 2006; 5 Johnson, Burnell-Nugent, Lossignol (CR15) 2010; 39 Huestis (CR14) 2007; 4 Kemp, Abukhalaf, Manno, Manno, Alford, Abusada (CR17) 1995; 19 Yamaori, Kushihara, Yamamoto, Watanabe (CR30) 2010; 79 Russo (CR27) 2011; 163 Furuta, Shirai, Sugimoto, Nakamura, Hishida, Ishizaki (CR10) 2005; 20 Johnson, Lossignol, Burnell-Nugent, Fallon (CR16) 2012 Constantinescu, Sarantis (CR3) 2006; 12 Whittle, Guy, Robson (CR29) 2001; 1 Guengerich (CR12) 2008; 21 (CR7) 2012 Cupp, Tracy (CR4) 1998; 57 JR Johnson (303_CR16) 2012 CS Constantinescu (303_CR3) 2006; 12 R Porteney (303_CR24) 2012; 13 RG Pertwee (303_CR23) 2007; 36 RL Foltz (303_CR9) 1983; 10 JR Johnson (303_CR15) 2010; 39 CR Goodall (303_CR11) 1995; 19 TM Bland (303_CR1) 2005; 70 Division of Clinical Pharmacology (303_CR6) 2012 DJ Rog (303_CR26) 2007; 29 MP Kemp (303_CR17) 1995; 19 MA Huestis (303_CR14) 2007; 4 JC Miller (303_CR20) 1992 FDA Guidance for Industry (303_CR7) 2012 CC Ogu (303_CR22) 2000; 13 Federal Drug Association (303_CR8) 2012 AC Howlett (303_CR13) 2002; 54 RM Langford (303_CR18) 2013; 260 BA Whittle (303_CR29) 2001; 1 TJ Nurmikko (303_CR21) 2007; 133 MJ Cupp (303_CR4) 1998; 57 FP Guengerich (303_CR12) 2008; 21 T Furuta (303_CR10) 2005; 20 S Yamaori (303_CR30) 2010; 79 EL Michalets (303_CR19) 1998; 18 DJ Rog (303_CR25) 2005; 8 J Chen (303_CR2) 2006; 5 EB Russo (303_CR27) 2011; 163 CG Stott (303_CR28) 2012 JT DiPiro (303_CR5) 1999 23141881 - J Pain Symptom Manage. 2013 Aug;46(2):207-18 6305440 - Biomed Mass Spectrom. 1983 May;10(5):316-23 20117100 - Biochem Pharmacol. 2010 Jun 1;79(11):1691-8 23179176 - Eur J Clin Pharmacol. 2013 May;69(5):1135-47 16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3 17952649 - Mol Neurobiol. 2007 Aug;36(1):45-59 12037135 - Pharmacol Rev. 2002 Jun;54(2):161-202 8926736 - J Anal Toxicol. 1995 Oct;19(6):419-26 17712819 - Chem Biodivers. 2007 Aug;4(8):1770-804 18035205 - Clin Ther. 2007 Sep;29(9):2068-79 16480505 - Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3 16186518 - Neurology. 2005 Sep 27;65(6):812-9 22483680 - J Pain. 2012 May;13(5):438-49 16112652 - Biochem Pharmacol. 2005 Oct 1;70(7):1096-103 19896326 - J Pain Symptom Manage. 2010 Feb;39(2):167-79 23180178 - J Neurol. 2013 Apr;260(4):984-97 9447218 - Am Fam Physician. 1998 Jan 1;57(1):107-16 17997224 - Pain. 2007 Dec 15;133(1-3):210-20 15988117 - Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67 7500614 - J Anal Toxicol. 1995 Sep;19(5):285-91 18052394 - Chem Res Toxicol. 2008 Jan;21(1):70-83 21749363 - Br J Pharmacol. 2011 Aug;163(7):1344-64 9469685 - Pharmacotherapy. 1998 Jan-Feb;18(1):84-112 |
| References_xml | – year: 2012 ident: CR28 article-title: A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray publication-title: Eur J Clin Pharmacol – volume: 79 start-page: 1691 year: 2010 end-page: 8 ident: CR30 article-title: Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2010.01.028 – year: 2012 ident: CR8 publication-title: Drug development and drug interactions: table of substrates, inhibitors and inducers – year: 2012 ident: CR16 article-title: An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractive to strong opioid analgesia publication-title: J Pain Symptom Manage – volume: 12 start-page: 111 year: 2006 ident: CR3 article-title: Long-term open-label treatment with Sativex in patients with multiple sclerosis publication-title: Mult Scler – volume: 8 start-page: 283 year: 2005 end-page: 91 ident: CR25 article-title: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis publication-title: Neurology – volume: 19 start-page: 91 year: 1995 end-page: 285 ident: CR17 article-title: Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS publication-title: J Anal Tox doi: 10.1093/jat/19.2.91 – year: 1992 ident: CR20 publication-title: Statistics for analytical Chemistry – volume: 13 start-page: 421 issue: 4 year: 2000 end-page: 3 ident: CR22 article-title: Drug interactions due to cytochrome P450 publication-title: Proc (Bayl Univ Med Cent) – volume: 5 start-page: 3 year: 2006 ident: CR2 article-title: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor publication-title: Ann Clin Microbiol Antimicriob doi: 10.1186/1476-0711-5-3 – year: 2012 ident: CR6 publication-title: Indiana University Department of Medicine – volume: 260 start-page: 984 issue: 4 year: 2013 end-page: 97 ident: CR18 article-title: A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis publication-title: J Neurol doi: 10.1007/s00415-012-6739-4 – volume: 133 start-page: 210 year: 2007 end-page: 20 ident: CR21 article-title: Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial publication-title: Pain doi: 10.1016/j.pain.2007.08.028 – volume: 57 start-page: 107 year: 1998 end-page: 16 ident: CR4 article-title: Cytochrome P450: new nomenclature and clinical implications publication-title: Am Fam Physician – volume: 21 start-page: 70 issue: 1 year: 2008 end-page: 83 ident: CR12 article-title: Cytochrome p450 and chemical toxicology publication-title: Chem Res Toxicol doi: 10.1021/tx700079z – volume: 39 start-page: 167 issue: 2 year: 2010 end-page: 79 ident: CR15 article-title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2009.06.008 – volume: 163 start-page: 1344 year: 2011 end-page: 64 ident: CR27 article-title: Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects publication-title: BJP doi: 10.1111/j.1476-5381.2011.01238.x – volume: 29 start-page: 2068 issue: 9 year: 2007 end-page: 79 ident: CR26 article-title: Oromucosal delta-9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.09.013 – volume: 20 start-page: 153 issue: 3 year: 2005 end-page: 67 ident: CR10 article-title: Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.20.153 – volume: 36 start-page: 45 year: 2007 end-page: 59 ident: CR23 article-title: Cannabinoids and Multiple Sclerosis publication-title: Mol Neurobiol doi: 10.1007/s12035-007-0005-2 – volume: 10 start-page: 316 issue: 5 year: 1983 end-page: 23 ident: CR9 article-title: Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry publication-title: Biochemical MS – volume: 70 start-page: 1096 year: 2005 end-page: 103 ident: CR1 article-title: CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2005.07.007 – start-page: 29 year: 1999 end-page: 30 ident: CR5 publication-title: Pharmacotherapy: A Pathophysiologic Approach – volume: 54 start-page: 161 issue: 2 year: 2002 end-page: 202 ident: CR13 article-title: International union of pharmacology. XXVII. Classification of cannabinoid receptors publication-title: Pharmacol Rev doi: 10.1124/pr.54.2.161 – volume: 1 start-page: 183 issue: 3–4 year: 2001 end-page: 205 ident: CR29 article-title: Prospects for new cannabis-based prescription medicines publication-title: J Cannabis Therapeutics doi: 10.1300/J175v01n03_12 – volume: 19 start-page: 419 year: 1995 end-page: 26 ident: CR11 article-title: A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood publication-title: J Anal Tox doi: 10.1093/jat/19.6.419 – volume: 4 start-page: 1770 year: 2007 end-page: 804 ident: CR14 article-title: Human cannabinoid pharmacokinetics publication-title: Chem Biodivers doi: 10.1002/cbdv.200790152 – year: 2012 ident: CR7 publication-title: Bioanalytical Method Validation issued by the U.S Department of Health and Human Services Food and Drug Administration – volume: 18 start-page: 84 year: 1998 end-page: 112 ident: CR19 article-title: Update: clinically significant cytochrome P-450 drug interactions publication-title: Pharmacotherapy – volume: 13 start-page: 438 issue: 5 year: 2012 end-page: 49 ident: CR24 article-title: Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial publication-title: J Pain doi: 10.1016/j.jpain.2012.01.003 – volume: 5 start-page: 3 year: 2006 ident: 303_CR2 publication-title: Ann Clin Microbiol Antimicriob doi: 10.1186/1476-0711-5-3 – volume: 70 start-page: 1096 year: 2005 ident: 303_CR1 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2005.07.007 – volume: 260 start-page: 984 issue: 4 year: 2013 ident: 303_CR18 publication-title: J Neurol doi: 10.1007/s00415-012-6739-4 – volume: 13 start-page: 421 issue: 4 year: 2000 ident: 303_CR22 publication-title: Proc (Bayl Univ Med Cent) doi: 10.1080/08998280.2000.11927719 – volume: 29 start-page: 2068 issue: 9 year: 2007 ident: 303_CR26 publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.09.013 – volume: 19 start-page: 91 year: 1995 ident: 303_CR17 publication-title: J Anal Tox doi: 10.1093/jat/19.2.91 – volume: 79 start-page: 1691 year: 2010 ident: 303_CR30 publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2010.01.028 – volume-title: Drug development and drug interactions: table of substrates, inhibitors and inducers year: 2012 ident: 303_CR8 – volume: 18 start-page: 84 year: 1998 ident: 303_CR19 publication-title: Pharmacotherapy doi: 10.1002/j.1875-9114.1998.tb03830.x – volume: 4 start-page: 1770 year: 2007 ident: 303_CR14 publication-title: Chem Biodivers doi: 10.1002/cbdv.200790152 – volume-title: Eur J Clin Pharmacol year: 2012 ident: 303_CR28 – volume-title: Indiana University Department of Medicine year: 2012 ident: 303_CR6 – volume: 10 start-page: 316 issue: 5 year: 1983 ident: 303_CR9 publication-title: Biochemical MS – volume: 1 start-page: 183 issue: 3–4 year: 2001 ident: 303_CR29 publication-title: J Cannabis Therapeutics doi: 10.1300/J175v01n03_12 – volume: 12 start-page: 111 year: 2006 ident: 303_CR3 publication-title: Mult Scler – volume: 133 start-page: 210 year: 2007 ident: 303_CR21 publication-title: Pain doi: 10.1016/j.pain.2007.08.028 – volume: 163 start-page: 1344 year: 2011 ident: 303_CR27 publication-title: BJP doi: 10.1111/j.1476-5381.2011.01238.x – volume-title: Bioanalytical Method Validation issued by the U.S Department of Health and Human Services Food and Drug Administration year: 2012 ident: 303_CR7 – volume: 8 start-page: 283 year: 2005 ident: 303_CR25 publication-title: Neurology – volume: 21 start-page: 70 issue: 1 year: 2008 ident: 303_CR12 publication-title: Chem Res Toxicol doi: 10.1021/tx700079z – volume: 19 start-page: 419 year: 1995 ident: 303_CR11 publication-title: J Anal Tox doi: 10.1093/jat/19.6.419 – volume: 36 start-page: 45 year: 2007 ident: 303_CR23 publication-title: Mol Neurobiol doi: 10.1007/s12035-007-0005-2 – volume: 57 start-page: 107 year: 1998 ident: 303_CR4 publication-title: Am Fam Physician – start-page: 29 volume-title: Pharmacotherapy: A Pathophysiologic Approach year: 1999 ident: 303_CR5 – volume: 54 start-page: 161 issue: 2 year: 2002 ident: 303_CR13 publication-title: Pharmacol Rev doi: 10.1124/pr.54.2.161 – volume: 39 start-page: 167 issue: 2 year: 2010 ident: 303_CR15 publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2009.06.008 – volume: 20 start-page: 153 issue: 3 year: 2005 ident: 303_CR10 publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.20.153 – volume-title: J Pain Symptom Manage year: 2012 ident: 303_CR16 – volume-title: Statistics for analytical Chemistry year: 1992 ident: 303_CR20 – volume: 13 start-page: 438 issue: 5 year: 2012 ident: 303_CR24 publication-title: J Pain doi: 10.1016/j.jpain.2012.01.003 – reference: 9447218 - Am Fam Physician. 1998 Jan 1;57(1):107-16 – reference: 12037135 - Pharmacol Rev. 2002 Jun;54(2):161-202 – reference: 16480505 - Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3 – reference: 18052394 - Chem Res Toxicol. 2008 Jan;21(1):70-83 – reference: 17712819 - Chem Biodivers. 2007 Aug;4(8):1770-804 – reference: 18035205 - Clin Ther. 2007 Sep;29(9):2068-79 – reference: 23180178 - J Neurol. 2013 Apr;260(4):984-97 – reference: 6305440 - Biomed Mass Spectrom. 1983 May;10(5):316-23 – reference: 17952649 - Mol Neurobiol. 2007 Aug;36(1):45-59 – reference: 23141881 - J Pain Symptom Manage. 2013 Aug;46(2):207-18 – reference: 22483680 - J Pain. 2012 May;13(5):438-49 – reference: 20117100 - Biochem Pharmacol. 2010 Jun 1;79(11):1691-8 – reference: 21749363 - Br J Pharmacol. 2011 Aug;163(7):1344-64 – reference: 7500614 - J Anal Toxicol. 1995 Sep;19(5):285-91 – reference: 23179176 - Eur J Clin Pharmacol. 2013 May;69(5):1135-47 – reference: 9469685 - Pharmacotherapy. 1998 Jan-Feb;18(1):84-112 – reference: 8926736 - J Anal Toxicol. 1995 Oct;19(6):419-26 – reference: 16186518 - Neurology. 2005 Sep 27;65(6):812-9 – reference: 16389357 - Proc (Bayl Univ Med Cent). 2000 Oct;13(4):421-3 – reference: 19896326 - J Pain Symptom Manage. 2010 Feb;39(2):167-79 – reference: 17997224 - Pain. 2007 Dec 15;133(1-3):210-20 – reference: 15988117 - Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67 – reference: 16112652 - Biochem Pharmacol. 2005 Oct 1;70(7):1096-103 |
| SSID | ssj0000671470 |
| Score | 2.268336 |
| Snippet | This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol... This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of [Delta]9-tetrahydrocannabinol... |
| SourceID | pubmedcentral biomedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 236 |
| SubjectTerms | Biomedical and Life Sciences Humanities and Social Sciences Metabolites multidisciplinary Pharmacokinetics Science Science (multidisciplinary) Sprays |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LbxMxELYgvXBBlGegoEHi0Eox2fU-Iw6oDa0CiFJVrdTbyrs7VqNudkOSHtpf2p_DjOMElgCR9hD5LX8ejz3jb4R4p9D42vipDMJSyVB5JAdJzZekjPtJHBWkpfKF_rfjeHQefrmILtyF29y5Va5kohXUZVPwHXmfidn8mPRp7-P0h-SoUWxddSE07ostEsFp2hFbB4fHJ6frWxaSxX6YeI7Th-ro0woNpE9yWSqpmJi59c69am9PGzrnpuvkH_ZTuy0dPRIPnT4J-0sAbIt7WD8W227FzmHX0UrvPRF3-3BySXsWfO4Bx8ySNP9Y9YA2q7KZjG-x7IHtFDt1gqWdhXENC5psBGYIryqswL4CmcOiAccTjpQDYekWAo2B07HRkynb63vwFRcNnbf1bVNhD6gd-D7B6cz-h6a2JaeOO_uK1F2mjOY6zkbD_vDgEzSzZsIe9TRAGr-2_Vk-3LwBFqsECtJen4rzo8Oz4Ui6uA4y5_AJUodM-aIHSOpbwWZCE-ShTk2cxH5exkHio9alSrAYmNRDTHReRCUmyksH5cCY4Jno1E2NLwT4iHSCjXNtPB2mkcqLUg9ohjEyscqDoCs-tKY3my45PDJm1W6nENgyBkfG4MhURl3sivcrMGSFo0znyB1VZo9OabxZYHddYNXSP7PurNCVObExz36BvCverpNpwbMVR9fYXFMeOoLyl1AVz5dgXLelAmuW9rsiacG0Nex2Sj2-tKTiAa0U-nXF3grQv3Xr70N4-f8hvBIPlI0dEkkV7ojOYnaNr0mDW-Rv3DL9CcpsSRM priority: 102 providerName: ProQuest – databaseName: Springer Open Access Hybrid - NESLI2 2011-2012 dbid: 40G link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfGeOEFMT4LAx0SD5tUs9hJnFQ8jcIoID6ENmlvkZOctYo0qdrugf2l_DncuUlF1vFApTxUtmNb9-G73Pl3QrzS6JR1KpVhVGoZ6YD0IJn5koxxlZi4ICuVP-h_-WomZ9Gn8_h8R6juLozPdu9Ckl5Te7FOzRGJVigVKVSppQ7NLXGbscSYkaPgw-azCilfFSVBC-Jzw7hrF9ur_nm0ZWRu50peC5j6c-jknrjbGpBwvKb4ntjB-r7Ya0V0CQctjvThA_H7GL5f0CEFH4fARbIkERyrIdDpVDaz6RWWQ_CL4ixO8DizMK1hRdRFYEjwqsIK_LWPJawaaIHBkXogrPNAoHHwY-rsbM4B-iF8xlVDDra9aiocAs0D32Y4X_j_0NR-5LwFy_5J9i1jRPM7Tifjo_Hbd9Asmhmn0NMGaf_Wr2d9U_MXsB4lLiBz9aE4O3l_Op7ItpCDzLlegrQRY7zYEZK9VnBc0IV5ZFNnEqPy0oSJQmtLnWAxcmmAmNi8iEtMdJCOypFz4SOxWzc1PhGgEMllNbl1gY3SWOdFaUdEYYyd0XkYDsSbHnmz-Rq0I2MY7X4LMVfGzJExc2Q6oyUOxOuOGbKixUjnUh1V5n2l1GwPONgM6Gb6Z9f9jruyVk8sM4YbVIa8xGAgXm6aScI5bGNrbC6pD_mc_CT0isdrZtzMpUMfh1YDkfTYtLftfks9vfAo4iFJCv0G4rBj6L-WdfMWnv5H32fijvaVQ2Kpo32xu1pc4nOy31b5Cy-xfwDkhELK priority: 102 providerName: Springer Nature |
| Title | A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers |
| URI | https://link.springer.com/article/10.1186/2193-1801-2-236 https://www.ncbi.nlm.nih.gov/pubmed/23750331 https://www.proquest.com/docview/1866165500 https://www.proquest.com/docview/1626162676 http://dx.doi.org/10.1186/2193-1801-2-236 https://pubmed.ncbi.nlm.nih.gov/PMC3671111 |
| Volume | 2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELfY9sILYvztGNMh8bBJ9ZY4iZMKIbSVlQLamKZN2lvkJGetIk1K20lsn5SPw9l1C1kLlWopsh376jvfXc_-HWNvBWpfaT_hQVgIHgqP9kEy8zkZ434so5ysVPOH_smp7F-GX66iqz_pgNwPOFnp2pl8Upfjcv_nj9sPJPDvrcAn8oCELuA-bbVccBHINbZBaik26QxOnK3vtmU_jD0H77Oi370r72VTUy2Zn8unKO-FUq2G6j1mj5xpCYczXthkD7B6wjad8E5g1yFM7z1lvw7h7JrUF3xugyGXEytg2QbSW0U9HNxh0QY7KXO-EywCLQwqmNK6Ixiw8LLEEuyFkAlMa3CQ4UgtEGYnRKDWcD7Qajgyofs2fMVpTa63uqtLbAONA9-GOBrbZ6gr23PkYLS_k-Vr0KPNOy763YPu0Ueox_XQHK4nAol-Zeczu8N5C2aHJf4gQ_YZu-wdX3T73KV44JnJpMBVaNBfVAfJkstNxFAHWagSLWPpZ4UMYh-VKkSMeUcnHmKssjwqMBZe0ik6WgfP2XpVV_iSgY9IzqzMlPZUmEQiywvVoRXGSEuRBUGLvWssbzqawXmkBmC7WUOynhrmSA1zpCKlKbbY_pwZ0tyhp5skHmVqvahELnfYXXSYj_TPpttz7krnApAaIEJfkv_otdibRTXJvgnoqArrG2pD3qj5xvSKFzNmXIwlAhuh9lssbrBpg-xmTTW4tvjiAUkKfVpsb87Qf01rNQlb_yfhFXsobBqRiItwm61Pxzf4moy5abbD1kLvE5VJj8qNo-PTs3N66orQlLK7Y4X4N66VTvI |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2V8gAviHINFBgkkFopJvb6GiGESkpISFsQSqW-mbU9ViMcOySpUPtRfA-fw8zaDpgAb43kh2jv2rNz2Z09K8QziamlUiswbCeRhiNNkoNk5htkjFu-58ZkpfKG_uGRNzh23p-4Jxvie30XhsMqa5moBXVSxLxH3mFiNssje9p8Pftq8KtRfLpaP6FRwmKE59_IZVu8Gu7T_D6Xsv923BsY1asCRsTk_YZymHBEdZGMh5gPqVI7clSQeuTQR4ln-xYqlUgf424amIi-imI3QV-aQTfppqlN9V4RVx2bNDnfTO-_W-3pkOS3HN-sGISoxx2SB7ZhkRYwpCGZBrpxqz5rKsM1C3c9UPOP01qtBPs3xY3KeoW9Em5bYgPzW2Krkg8L2KlIrHdvix978PGUNCQM28AvdBmENszaQKoxKaaTC0zaoDvFIaSgSW5hksOSoIXAfORZhhnoOycLWBZQsZIj5UAog1CgSOHTJFXTGUcHtGGEy4K8e3VRZNgGagc-THE21_-hyHXJWcXU_YWMayao5jrGg16n92Yfinkx5fh9GiCNX-n-lNdEz4GFOEGQbOU74vhS5vuu2MyLHO8LsBDJX_YilZrKCVwZxYnq0gyjm3oysu2WeNmY3nBWMoaEzOHdTCFohwyOkMERypC62BIvajCEcUXQzu-EZKF21AJvvcDOqkDd0j-zbtfoCishtQh_LamWeLpKJvHCZ0Yqx-KM8pDDy59PVdwrwbhqS9r6ENxqCb8B08awmyn55FRTmNu0UujXErs1oH_r1t-H8OD_Q3girg3GhwfhwfBo9FBcl_rVEteQzrbYXM7P8BHZjsvosV6wID5ftoT4Cc19haM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkBAviPG3MOCQQNqkZk2cxEmFeBgtU0thTGiT9hac5KxVpEnVZkLbd-L78HE4O0lF1vHAwyLlIfK_s_zz-S4-_8zYG47KkcoJLddLueVxm_QgmfkWGeNOIPyErFT9Q__LoRideJ9O_dMN9qs5C2Oi3ZstyepMg2ZpysvePFXVFA9Fj6aZazmkXC1ucVfUMZUTvPhJHtvy_XhIw_uW84OPx4ORVV8qYMWau9-SnuYbkX0k2yHRe1TKjT0ZKkH-fJwKN3BQypQHmPRVaCMGMk78FANuh_20r5RL9d5it8ktcrSvNxCD1S8dUvyOF9g1gdA1cl45VJ-118I1A3c9TvPKZq1ZAw_us3u18Qr7Fdq22AbmD9hWrR6WsFNzWO8-ZL_34eiMFkgYd0Ff0GUR2DDrAq2MaTGbXmLaBSOUjiAFw3EL0xxKQhaCpiPPMszAHDlZQllATUqOlAOhikGBQsG3qZKzuQ4O6MIEy4JGUV4WGXaB2oGvM5wvzDcUuSk5r4m6f5BtrfmpdR3Ho0Fv8GEIxaKY6fB96iD1Xxp5qlOiF6B1OOGDTOVH7ORGxvsx28yLHJ8ycBDJXRaxVLb0Qp_HSSr7NMLoK8Fj1-2wd63hjeYVYUikKbzbKQTsSIMj0uCIeEQidtheA4YoqfnZ9TUhWWT8tFCsF9hZFWha-mfW7QZdUa2jlpGmOnQEeah2h71eJZN20VtGMsfinPKQv6vfgKp4UoFx1RZ3zR6402FBC6atbrdT8umZYTB3aabQ02G7DaD_Euv6Ljz7j7yv2J2j4UH0eXw4ec7ucnOBiW9xb5ttlotzfEFmZBm_NJMX2Peb1hZ_ACchhTE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Phase+I%2C+open-label%2C+randomized%2C+crossover+study+in+three+parallel+groups+to+evaluate+the+effect+of+Rifampicin%2C+Ketoconazole%2C+and+Omeprazole+on+the+pharmacokinetics+of+THC%2FCBD+oromucosal+spray+in+healthy+volunteers&rft.jtitle=SpringerPlus&rft.au=Stott%2C+Colin&rft.au=White%2C+Linda&rft.au=Wright%2C+Stephen&rft.au=Wilbraham%2C+Darren&rft.date=2013-05-24&rft.pub=Springer+Nature+B.V&rft.eissn=2193-1801&rft.volume=2&rft.issue=1&rft.spage=1&rft_id=info:doi/10.1186%2F2193-1801-2-236&rft.externalDocID=4312882001 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-1801&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-1801&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-1801&client=summon |